Non-Hodgkin's Lymphoma - Outlook

Outlook for Aggressive (Intermediate- to High-Grade) Lymphomas

High-grade aggressive lymphomas are often symptomatic early on and are potentially curable with aggressive treatments. Diffuse large-cell lymphomas, the most common aggressive non-Hodgkin's lymphomas, while fatal if not treated, are often curable with intensive chemotherapy combinations. If relapse occurs after chemotherapy, it usually does so within 2 years.

text continues below

Most other aggressive lymphomas respond to aggressive chemotherapy. Mantle cell lymphoma is less responsive to chemotherapy. The average survival time is 3 to 5 years.

Factors for Predicting Outlook in Aggressive Lymphomas: A scoring system called the International Prognostic Index has proved to be fairly accurate for predicting outcome in patients with most aggressive B-cell lymphomas. It uses five risk factors to help predict whether the disease will be aggressive:

Being older than 60 -- this age group tends to have other medical conditions, which contribute to the poorer prognosis
Having a disseminated tumor (stage III or IV)
Disease that has spread to more than one site beyond the lymph nodes
A poor performance status
Having elevated levels of lactate dehydrogenase (LDH)

Having one or none of these risk factors indicates the best outlook; two factors indicate a low to intermediate likelihood of a poor outlook; three factors predict an intermediate to high likelihood of poor outlooks; and four or five factors pose the highest likelihood of poor survival.

Risk Factors for Central Nervous System Involvement

Lymphoma can spread to the central nervous system or it can appear there first, which is referred to as primary CNS lymphomas (PCNSL). It is a very serious event, particularly if it occurs at relapse.

The central nervous system is comprised of the brain and spinal cord. The peripheral nervous system includes all peripheral nerves.

Risk Factors for CNS Involvement After a Diagnosis of NHL. According to a 2002 study, the risk for CNS involvement in low-grade NHL is about 2.8%. Among patients with high-grade NHL, those with lymphoblastic and Burkitt's lymphoma are at high risk (nearly 25%) for recurrence in the central nervous system. For other patients with high-grade NHL, the 5-year risk was slightly over 5%, although having other factors increased this danger.

Risk Factors of Primary CNS Lymphomas. PCNSL used to account for only about 2% of lymphomas but the incidence is on the rise in all age groups and in both. The reason for the increase is not known.